Latest Valence8 US LP Stock Portfolio
Valence8 US LP Performance:
2024 Q3: 1.33%YTD: 4.69%2023: 6.17%
Performance for 2024 Q3 is 1.33%, and YTD is 4.69%, and 2023 is 6.17%.
About Valence8 US LP and 13F Hedge Fund Stock Holdings
Valence8 US LP is a hedge fund based in CAMBRIDGE, MA. On 18-Sep-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $574.6 Millions. In it's latest 13F Holdings report, Valence8 US LP reported an equity portfolio of $241.1 Millions as of 30 Sep, 2024.
The top stock holdings of Valence8 US LP are IBCE, QQQ, ACWF. The fund has invested 25.1% of it's portfolio in ISHARES TR and 17.8% of portfolio in INVESCO QQQ TR.
They significantly reduced their stock positions in SELECT SECTOR SPDR TR (XLB), ISHARES TR (AGT) and VANGUARD INDEX FDS (VB). Valence8 US LP opened new stock positions in JAZZ PHARMACEUTICALS PLC (JAZZ), BRISTOL-MYERS SQUIBB CO (BMY) and ASCENDIS PHARMA A/S. The fund showed a lot of confidence in some stocks as they added substantially to ISHARES TR (ACWF), INVESCO QQQ TR (QQQ) and ISHARES TR (IBCE).
The top stock holdings of Valence8 US LP are IBCE, QQQ, ACWF. The fund has invested 25.1% of it's portfolio in ISHARES TR and 17.8% of portfolio in INVESCO QQQ TR.
They significantly reduced their stock positions in SELECT SECTOR SPDR TR (XLB), ISHARES TR (AGT) and VANGUARD INDEX FDS (VB). Valence8 US LP opened new stock positions in JAZZ PHARMACEUTICALS PLC (JAZZ), BRISTOL-MYERS SQUIBB CO (BMY) and ASCENDIS PHARMA A/S. The fund showed a lot of confidence in some stocks as they added substantially to ISHARES TR (ACWF), INVESCO QQQ TR (QQQ) and ISHARES TR (IBCE).
Valence8 US LP Annual Return Estimates Vs S&P 500
Our best estimate is that Valence8 US LP made a return of 1.33% in the last quarter. In trailing 12 months, it's portfolio return was 9.8%.
New Buys
| Ticker | $ Bought |
|---|---|
| jazz pharmaceuticals plc | 999,236 |
| bristol-myers squibb co | 920,196 |
| ascendis pharma a/s | 684,586 |
| insmed inc | 574,145 |
| indivior plc | 564,186 |
| eli lilly & co | 560,800 |
| argenx se | 516,602 |
| soleno therapeutics inc | 490,056 |
New stocks bought by Valence8 US LP
Additions
| Ticker | % Inc. |
|---|---|
| ishares tr | 15.03 |
| invesco qqq tr | 14.91 |
| ishares tr | 12.1 |
Additions to existing portfolio by Valence8 US LP
Reductions
| Ticker | % Reduced |
|---|---|
| select sector spdr tr | -6.56 |
| ishares tr | -3.5 |
| vanguard index fds | -3.37 |
| select sector spdr tr | -1.8 |
Valence8 US LP reduced stake in above stock
Sold off
Sector Distribution
Valence8 US LP has about 96.7% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 96.7 |
| Healthcare | 3.3 |
Market Cap. Distribution
Valence8 US LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 96.7 |
| MID-CAP | 1.4 |
Stocks belong to which Index?
About 1.8% of the stocks held by Valence8 US LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 97.6 |
| RUSSELL 2000 | 1.8 |
Valence8 US LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Valence8 US LP
Valence8 US LP has 40 stocks in it's portfolio. About 91.4% of the portfolio is in top 10 stocks. ENTA proved to be the most loss making stock for the portfolio. XLB was the most profitable stock for Valence8 US LP last quarter.
Last Reported on: 12 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AAXJ | ishares tr | 9.53 | 399,186 | 22,965,200 | unchanged | 0.00 | ||
| ACWF | ishares tr | 17.66 | 1,026,290 | 42,580,800 | added | 15.03 | ||
| AGT | ishares tr | 3.25 | 209,344 | 7,831,560 | reduced | -3.5 | ||
| ALEC | alector inc | 0.03 | 14,708 | 68,539 | new | |||
| BMY | bristol-myers squibb co | 0.38 | 17,785 | 920,196 | new | |||
| BPMC | blueprint medicines corp | 0.10 | 2,618 | 242,165 | new | |||
| CRNX | crinetics pharmaceuticals in | 0.14 | 6,684 | 341,552 | new | |||
| ELYM | eliem therapeutics inc | 0.03 | 12,045 | 61,309 | new | |||
| EMGF | ishares inc | 3.22 | 108,634 | 7,771,680 | unchanged | 0.00 | ||
| ENTA | enanta pharmaceuticals inc | 0.09 | 19,939 | 206,568 | new | |||
| ERAS | erasca inc | 0.05 | 46,923 | 128,100 | new | |||
| IBCE | ishares tr | 25.10 | 337,472 | 60,508,700 | added | 12.1 | ||
| INSM | insmed inc | 0.24 | 7,865 | 574,145 | new | |||
| JANX | janux therapeutics inc | 0.15 | 7,857 | 356,944 | new | |||
| JAZZ | jazz pharmaceuticals plc | 0.41 | 8,969 | 999,236 | new | |||
| KROS | keros therapeutics inc | 0.19 | 8,025 | 466,012 | new | |||
| KZR | kezar life sciences inc | 0.01 | 2,113 | 16,342 | new | |||
| LLY | eli lilly & co | 0.23 | 633 | 560,800 | new | |||
| LPTX | leap therapeutics inc | 0.02 | 18,511 | 47,573 | new | |||
| NKTR | nektar therapeutics | 0.01 | 26,107 | 33,939 | new | |||